Published in Cancer Res on February 01, 2001
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment | NCT02864030
Drug development from marine natural products. Nat Rev Drug Discov (2008) 4.08
Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry (2010) 2.07
Synthesis at the molecular frontier. Nature (2009) 2.03
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2015) 1.85
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther (2008) 1.78
Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer (2014) 1.38
Marketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for success. Mar Drugs (2014) 1.26
Interactions of halichondrin B and eribulin with tubulin. J Chem Inf Model (2011) 1.19
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer (2013) 1.16
Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel. Cell Cycle (2011) 1.16
What lies underneath: conserving the oceans' genetic resources. Proc Natl Acad Sci U S A (2010) 1.14
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci (2014) 1.13
Eribulin mesylate in patients with refractory cancers: a Phase I study. Invest New Drugs (2011) 1.13
Chemical Diversity of Metabolites from Fungi, Cyanobacteria, and Plants Relative to FDA-Approved Anticancer Agents. ACS Med Chem Lett (2012) 1.11
Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol Cancer Ther (2009) 1.10
Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer (2013) 1.05
Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin. Sci Transl Med (2014) 1.01
Cancer across the tree of life: cooperation and cheating in multicellularity. Philos Trans R Soc Lond B Biol Sci (2015) 1.00
Eribulin -- a review of preclinical and clinical studies. Crit Rev Oncol Hematol (2011) 0.94
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest New Drugs (2012) 0.93
Eribulin mesylate in the treatment of metastatic breast cancer. Biologics (2012) 0.92
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res (2015) 0.92
Design, synthesis, and biological evaluation of diminutive forms of (+)-spongistatin 1: lessons learned. J Am Chem Soc (2011) 0.91
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat (2013) 0.91
Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer. Onco Targets Ther (2011) 0.89
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist (2014) 0.89
Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. Springerplus (2014) 0.89
Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs (2009) 0.89
Eribulin for advanced breast cancer: a drug evaluation. J Breast Cancer (2013) 0.88
Oridonin-induced apoptosis in SW620 human colorectal adenocarcinoma cells. Oncol Lett (2011) 0.85
Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells. PLoS One (2014) 0.85
ELR510444, a novel microtubule disruptor with multiple mechanisms of action. J Pharmacol Exp Ther (2010) 0.84
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs (2011) 0.84
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. Cancer (2011) 0.83
Eribulin drug review. South Asian J Cancer (2014) 0.83
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. Br J Clin Pharmacol (2013) 0.83
Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer. Invest New Drugs (2014) 0.82
Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int J Womens Health (2015) 0.82
Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol (2015) 0.81
Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro. Vasc Cell (2014) 0.81
Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells. PLoS One (2014) 0.81
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer. Breast Cancer (Dove Med Press) (2011) 0.81
Eribulin in Cancer Treatment. Mar Drugs (2015) 0.80
Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas. Indian J Med Paediatr Oncol (2016) 0.80
Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life. Springerplus (2016) 0.80
Is there no end to the total syntheses of strychnine? Lessons learned in strategy and tactics in total synthesis. Angew Chem Int Ed Engl (2012) 0.79
Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer (2014) 0.79
Novel microtubule-targeted agent 6-chloro-4-(methoxyphenyl) coumarin induces G2-M arrest and apoptosis in HeLa cells. Acta Pharmacol Sin (2012) 0.79
Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis. Angew Chem Int Ed Engl (2016) 0.78
A novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cells. PLoS One (2013) 0.78
Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates. Med Res Rev (2015) 0.78
Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival. Onco Targets Ther (2016) 0.77
Eribulin targets a ch-TOG-dependent directed migration of cancer cells. Oncotarget (2015) 0.77
Anticancer properties of novel aminoacetonitrile derivative monepantel (ADD 1566) in pre-clinical models of human ovarian cancer. Am J Cancer Res (2014) 0.77
A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium. Br J Cancer (2015) 0.76
The modification of natural products for medical use. Acta Pharm Sin B (2016) 0.75
Nature's bounty - drug discovery from the sea. Expert Opin Drug Discov (2007) 0.75
Efficacy of eribulin in breast cancer: a short report on the emerging new data. Onco Targets Ther (2017) 0.75
Functionally Optimized Neuritogenic Farinosone C Analogs: SAR-Study and Investigations on Their Mode of Action. ACS Med Chem Lett (2013) 0.75
Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide. J Breast Cancer (2016) 0.75
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer (Auckl) (2016) 0.75
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products. Drugs (2015) 0.75
Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer. Mol Clin Oncol (2015) 0.75
A novel natural phenyl alkene with cytotoxic activity. Tetrahedron Lett (2013) 0.75
Exploratory research on bioactive natural products with a focus on biological phenomena. Proc Jpn Acad Ser B Phys Biol Sci (2010) 0.75
Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings. Breast Cancer (Auckl) (2015) 0.75
Potential clinical applications of halichondrins in breast cancer and other neoplasms. Breast Cancer (Dove Med Press) (2012) 0.75
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance. Breast Cancer Res Treat (2016) 0.75
Microtubule-Targeting Agents Eribulin and Paclitaxel Differentially Affect Neuronal Cell Bodies in Chemotherapy-Induced Peripheral Neuropathy. Neurotox Res (2017) 0.75
Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition. Oncol Rep (2016) 0.75
Eribulin shows high concentration and long retention in xenograft tumor tissues. Cancer Chemother Pharmacol (2017) 0.75
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J (1982) 17.98
Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science (2009) 13.45
Complete genome sequence of Methanobacterium thermoautotrophicum deltaH: functional analysis and comparative genomics. J Bacteriol (1997) 12.21
p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell (1998) 11.54
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res (1994) 9.00
Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med (2000) 8.47
Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95
The frequency of chimeric molecules as a consequence of PCR co-amplification of 16S rRNA genes from different bacterial species. Microbiology (1996) 7.78
Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron (1996) 7.20
Frequency of formation of chimeric molecules as a consequence of PCR coamplification of 16S rRNA genes from mixed bacterial genomes. Appl Environ Microbiol (1997) 7.09
A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature (1996) 7.04
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science (1999) 6.93
TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem Biophys Res Commun (1999) 6.33
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med (1997) 5.93
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
A cluster of hydrophobic amino acid residues required for fast Na(+)-channel inactivation. Proc Natl Acad Sci U S A (1992) 5.60
Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol (1997) 5.49
Deficient hippocampal long-term potentiation in alpha-calcium-calmodulin kinase II mutant mice. Science (1992) 5.46
Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med (2001) 5.43
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res (1998) 5.41
Genetic diversity and disease control in rice. Nature (2000) 5.34
A role for the lissencephaly gene LIS1 in mitosis and cytoplasmic dynein function. Nat Cell Biol (2000) 5.29
Racial differences in the use of cardiac catheterization after acute myocardial infarction. N Engl J Med (2001) 5.29
Organizing principles for a diversity of GABAergic interneurons and synapses in the neocortex. Science (2000) 5.27
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A (1997) 4.89
Differential signaling via the same axon of neocortical pyramidal neurons. Proc Natl Acad Sci U S A (1998) 4.59
POWER_SAGE: comparing statistical tests for SAGE experiments. Bioinformatics (2000) 4.56
BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci (2001) 4.54
Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A (1996) 4.45
Do "America's Best Hospitals" perform better for acute myocardial infarction? N Engl J Med (1999) 4.30
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
Fringe is a glycosyltransferase that modifies Notch. Nature (2000) 4.09
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science (1999) 4.08
Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst (2000) 4.03
Validity and reproducibility of the food frequency questionnaire used in the Shanghai Women's Health Study. Eur J Clin Nutr (2004) 3.92
Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci U S A (1994) 3.85
Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci U S A (1996) 3.78
Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat Genet (1997) 3.69
Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Proc Natl Acad Sci U S A (1995) 3.68
The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. Neuron (2001) 3.68
Signal timing across the macaque visual system. J Neurophysiol (1998) 3.66
Multicentre trials of praziquantel in human schistosomiasis: design and techniques. Bull World Health Organ (1979) 3.59
The alternative oxidase lowers mitochondrial reactive oxygen production in plant cells. Proc Natl Acad Sci U S A (1999) 3.53
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet (2004) 3.45
The ica locus of Staphylococcus epidermidis encodes production of the capsular polysaccharide/adhesin. Infect Immun (1998) 3.44
Cooperative interaction of S. pombe proteins required for mating and morphogenesis. Cell (1994) 3.41
Focal adhesion kinase is involved in mechanosensing during fibroblast migration. Proc Natl Acad Sci U S A (2001) 3.41
A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature (1999) 3.40
Midzone microtubule bundles are continuously required for cytokinesis in cultured epithelial cells. J Cell Biol (1996) 3.36
Criteria and recommendations for vitamin C intake. JAMA (1999) 3.32
Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet (2001) 3.27
Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry (1998) 3.26
Male fertility potential in terms of semen quality: a review of the past, a study of the present. Fertil Steril (1979) 3.19
Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J Biol Chem (1987) 3.19
The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation (1978) 3.19
Identification of toxicants in cinnamon-flavored electronic cigarette refill fluids. Toxicol In Vitro (2014) 3.10
Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int (2007) 3.06
Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A (1998) 3.05
Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci (2000) 3.00
Changes in reliability of synaptic function as a mechanism for plasticity. Nature (1994) 2.97
Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med (1996) 2.96
Facilitation and depression at single central synapses. Neuron (1995) 2.95
Vam3p structure reveals conserved and divergent properties of syntaxins. Nat Struct Biol (2001) 2.92
Effectiveness of laser therapy and topical desensitising agents in treating dentine hypersensitivity: a systematic review. J Oral Rehabil (2011) 2.91
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr (2010) 2.91
A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science (1997) 2.90
Mammalian eukaryotic initiation factor 2 alpha kinases functionally substitute for GCN2 protein kinase in the GCN4 translational control mechanism of yeast. Proc Natl Acad Sci U S A (1993) 2.90
Are all wheezing disorders in very young (preschool) children increasing in prevalence? Lancet (2001) 2.90
Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J Biol Chem (2000) 2.89
Coronectomy vs. total removal for third molar extraction: a systematic review. J Dent Res (2012) 2.84
Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release (2001) 2.84
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet (1999) 2.83
Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol (1995) 2.79
Kinetochore localisation and phosphorylation of the mitotic checkpoint components Bub1 and BubR1 are differentially regulated by spindle events in human cells. J Cell Sci (2001) 2.76
Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP. Nat Genet (2001) 2.75
Distinct types of rRNA operons exist in the genome of the actinomycete Thermomonospora chromogena and evidence for horizontal transfer of an entire rRNA operon. J Bacteriol (1999) 2.72
Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J (2000) 2.71
Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol (2001) 2.70
A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res (1999) 2.69
Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J Exp Med (1998) 2.69
Feasibility of a high-speed gamma-camera design using the high-yield-pileup-event-recovery method. J Nucl Med (2001) 2.69
A high-affinity iron permease essential for Candida albicans virulence. Science (2000) 2.68
Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell (1999) 2.68
Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci U S A (1998) 2.68
Characterization of a protein cofactor that mediates protein kinase A regulation of the renal brush border membrane Na(+)-H+ exchanger. J Clin Invest (1995) 2.65
3D computational imaging with single-pixel detectors. Science (2013) 2.63
Heme-regulated eIF2alpha kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency. EMBO J (2001) 2.62
Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes Rev (2008) 2.62
Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer (2000) 2.62
A population-based case-control study of childhood leukemia in Shanghai. Cancer (1988) 2.59
Multicentre clinical trials of benzimidazolecarbamates in human echinococcosis. Bull World Health Organ (1986) 2.57
Genome-wide identification of NBS genes in japonica rice reveals significant expansion of divergent non-TIR NBS-LRR genes. Mol Genet Genomics (2004) 2.56